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Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment 
of the requirement for the degree of Master of Science 
 
CLONING AND EXPRESSION OF RECOMBINANT HUMAN EPIDERMAL 
GROWTH FACTOR IN Escherichia coli 
 
By 
 
AHMAD FAIZAL ABDULL RAZIS 
 
September 2007 
Chairman: Associate Professor Zarida Hambali, PhD 
Institute: Institute of Bioscience 
 
The expression of recombinant hEGF (human epidermal growth factor) in 
Escherichia coli was conducted to produce hEGF with free of inclusion bodies and 
biologically active. The recombinant hEGF was constructed using sticky ends 
ligation and resulted in successful insertion of the hEGF gene into the multiple 
cloning sites of the pFLAG-ATS. This insertion was confirmed by restriction 
enzyme analysis, PCR (polymerase chain reaction) and DNA (deoxyribonucleic 
acid) sequencing with 100% homology. The recombinant hEGF was expressed in E. 
coli at 2, 4 and 6 hours with induction of 0.5 mM and 1.0 mM IPTG 
(isopropylthiogalactopyranoside).This recombinant was found to be expressed as 
periplasmic fraction and whole cell insoluble fraction as confirmed with SDS-PAGE 
(sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and western blotting 
analyses. These analyses showed the molecular weight of hEGF was approximately 
6.8 kDa. There was no significant difference in the production of hEGF when the 
expression was induced with different IPTG concentration; however, for each IPTG 
concentration, there was significant difference between 0 hour and all the post-
induction hours. In addition, hEGF was found to be significantly higher in 
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periplasmic fraction as compared to the whole cell insoluble fraction (196.5 ng/ml as 
compared with 167 ng/ml at 2 hour, 175.7 ng/ml as compared with 115.3 ng/ml at 4 
hour and 168.3 ng/ml as compared with 140 ng/ml at 6 hour). Growth-stimulating 
activity of periplasmic hEGF was studied using BrdU (bromodeoxyuridine) cell 
proliferation assay and MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide) cell proliferation assay. The periplasmic hEGF as compared to the standard 
hEGF was found to be biologically active and showed similar activity. There were 
significant findings of periplasmic hEGF in stimulating the growth of HEK (human 
epidermal keratinocytes) at 24, 48 and 72 hours of incubation. Even at the highest 
concentration of periplasmic hEGF (10 ng/ml), the growth-stimulating activity still 
occurred and incubation at 48 hour resulted with the highest stimulation (85.4% at 10 
ng/ml, 77.7% at 1 ng/ml, 70.7% at 0.1 ng/ml, 55.9% at 0.01 ng/ml and 37.6% at 
0.001 ng/ml). Besides, MTT cell proliferation assay of periplasmic hEGF on HDF 
(human dermal fibroblasts) showed significant increased in the growth-stimulating 
activity when the duration of incubation increased. Highest percentage of HDF 
growth was found at 72 hour incubation as compared with 24 and 48 hours 
incubation. In conclusion, the findings showed recombinant hEGF was successfully 
expressed in E. coli and the growth-stimulating activity of hEGF was determined.  
 
 
 
 
 
 
 
 
 iv
Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai 
memenuhi keperluan untuk Ijazah Master Sains 
 
PENGKLONAN DAN PENGEKSPRESAN REKOMBINAN FAKTOR 
PERTUMBUHAN MANUSIA DALAM Escherichia coli 
 
Oleh 
AHMAD FAIZAL ABDULL RAZIS 
 
September 2007 
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Pengekspresan rekombinan faktor pertumbuhan manusia dalam Escherichia coli 
telah dijalankan untuk menghasilkan hEGF (human epidermal growth factor) bebas 
daripada badan inklusi dan aktif biologi. hEGF rekombinan telah dibentuk 
menggunakan kaedah percantuman hujung lekit dan hasilnya menunjukkan 
kemasukan gene hEGF ke pelbagai tapak klon pFLAG-ATS. Kemasukan gene ini 
telah dibuktikan melalui analisa enzim pembatas, PCR (polymerase chain reaction) 
dan penjujukan DNA (deoxyribonucleic acid) menunjukkan homologi 100%. hEGF 
rekombinan telah diekspres dalam E. coli pada jam 2, 4 dan 6 dengan diinduksi oleh 
0.5 mM dan 1.0 mM IPTG (isopropylthiogalactopyranoside). Rekombinan ini 
didapati telah diekspres sebagai fraksi periplasmik dan fraksi keseluruhan sel tak 
larut yang telah dibuktikan dengan analisa SDS-PAGE (sodium dodecyl sulphate-
polyacrylamide gel electrophoresis) dan kaedah ‘western blotting’. Keputusan ini 
menunjukkan berat molekul hEGF lebih kurang 6.8 kDa. Tiada perbezaan 
penghasilan hEGF apabila diinduksi dengan berbeza kepekatan IPTG. Walau 
bagaimanapun, untuk setiap kepekatan IPTG terdapat perbezaan ketara penghasilan 
hEGF diantara induksi pada jam 0 dan semua jam pasca induksi. Tambahan lagi, 
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kepekatan hEGF didapati lebih tinggi dalam fraksi periplasmik berbanding dengan 
fraksi keseluruhan sel tak larut (196.5 ng/ml berbanding 167 ng/ml pada jam 2, 175.7 
ng/ml berbanding 115.3 ng/ml pada jam 4 dan 168.3 ng/ml berbanding 140 ng/ml 
pada jam 6. Aktiviti rangsangan pertumbuhan oleh hEGF periplasmik telah dikaji 
menggunakan kaedah proliferasi sel BrdU (bromodeoxyuridine) dan MTT (3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide). hEGF periplasmik 
didapati aktif secara biologi dan mempuyai aktiviti yang sama apabila dibandingkan 
dengan Standard hEGF. Terdapat keputusan ketara menunjukkan hEGF periplasmik 
merangsang pertumbuhan HEK (human epidermal keratinocytes) pada jam 24, 48 
dan 72 inkubasi. Aktiviti rangsangan pertumbuhan masih berlaku meskipun pada 
kepekatan tertinggi hEGF periplasmik digunakan (10 ng/ml) dan inkubasi pada jam 
48 menunjukkan rangsangan yang tertinggi (85.4% pada kepekatan 10 ng/ml, 77.7% 
pada kepekatan 1 ng/ml, 70.7% pada kepekatan 0.1 ng/ml, 55.9% pada kepekatan 
0.01 ng/ml dan 37.6% pada kepekatan 0.001 ng/ml). Disamping itu, kaedah prolifersi 
sel MTT pada hEGF ke atas HDF (human dermal fibroblasts) menunjukkan 
pertambahan ketara dalam aktiviti rangsangan pertumbuhan dengan pertambahan 
tempoh inkubasi. Peratusan pertumbuhan HDF adalah tertinggi pada jam 72 inkubasi 
dalam perbandingan dengan inkubasi pada jam 24 dan jam 48. Kesimpulannya, 
keputusan menunjukkan bahawa hEGF rekombinan telah berjaya diekspres dalam E. 
coli dan aktiviti rangsangan pertumbuhannya telah ditentukan. 
 
 
 
 
 
 vi
ACKNOWLEDGEMENTS 
 
First of all, a lot of thanks to Utmost Allah the Almighty by His grace and bless, I 
have made this valuable accomplishment. 
 
Secondly, I would like to express my extremely grateful and deepest gratitude to my 
supervisor Assoc. Prof Dr. Zarida Hambali for her guidance, suggestion, attention, 
criticism and patience throughout the course of this study.  
 
My appreciation also goes to my co-supervisors Assoc. Prof Dr. Muhammad Nazrul 
Hakim Abdullah, Prof. Dr. Abdul Manaf Ali and Prof. Dr. Mohd Azmi Mohd Lila 
for their critical readings, discussion, comments and suggestions.    
 
Additionally, I would like to acknowledge Assoc. Prof Dr. Saidi Moin for his 
assistance in statistical analyses, Mr. Kamaruddin, Dr. Lai Kit Yee and Dr. Zeenathul 
Nazariah for their help and guidance in laboratory works and generously sharing 
their knowledge.  
 
I am grateful to all my friends at the Virology Laboratory, Faculty of Veterinary 
Medicine and Laboratory of Immunotherapeutics and Vaccines, Institute of 
Bioscience such as Mrs. Elysha, Suria, Hayati, Dr. Phong, Dr. Sandy, Kim Seng, 
Pong, Caryn, Lo, Tam, Kelvin, Nik Mohd Afizan, Mohd Razif, Fatema, Ram, 
Fadzlie Wong, and my housemates Radin Mohd Arif, Mohd Fazli, Azman, Huzairi, 
Termizi and Hafizuddin for their friendship.  
 vii
Finally, I would like to acknowledge my financial sponsor, the Malaysian Ministry 
of Science, Technology and Innovation (MOSTI) for National Science Fellowship 
(NSF) and IRPA grant, without the assistance, this research would not have made 
possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii
I certify that an Examination Committee has met on 10th September 2007 to conduct 
the final examination of Ahmad Faizal Abdull Razis on his Master of Science thesis 
entitled "Cloning and expression of recombinant human epidermal growth factor in 
Escherichia coli" in accordance with Universiti Pertanian Malaysia (Higher Degree) 
Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The 
Committee recommends that the student be awarded the degree of Master of Science.  
 
 
Members of the Examination Committee were as follows: 
 
 
Abdul Rahman Omar, PhD 
Associate Professor 
Faculty of Veterinary Medicine 
Universiti Putra Malaysia 
(Chairman) 
 
 
Raha Abd Rahim, PhD 
Professor 
Faculty of Biotechnology and Biomolecular Sciences 
Universiti Putra Malaysia 
(Internal Examiner) 
 
 
Latifah Saiful Yazan, PhD 
Lecturer 
Faculty of Medicine and Health Sciences 
Universiti Putra Malaysia 
(Internal Examiner) 
 
 
Sahidan Senafi, PhD 
Associate Professor 
Faculty of Science and Technology 
Universiti Kebangsaan Malaysia 
(External Examiner) 
 
 
 
            
                                                                        ________________________________ 
HASANAH MOHD. GHAZALI, PhD 
Professor and Deputy Dean 
School of Graduate Studies 
Universiti Putra Malaysia 
 
Date: 22 November 2007  
 ix
This thesis was submitted to the Senate of Universiti Putra Malaysia and has been 
accepted as fulfilment of the requirement for the degree of Master of Science. The 
members of the Supervisory Committee were as follows: 
 
 
Zarida Hambali, PhD 
Associate Professor 
Faculty of Medicine and Health Sciences 
Universiti Putra Malaysia 
(Chairman) 
 
 
Muhammad Nazrul Hakim Abdullah, PhD 
Associate Professor 
Faculty of Medicine and Health Sciences 
Universiti Putra Malaysia 
(Member) 
 
 
Abdul Manaf Ali, PhD 
Professor 
Faculty of Biotechnology and Biomolecular Sciences 
Universiti Putra Malaysia 
(Member) 
 
 
Mohd Azmi Mohd Lila, PhD 
Professor 
Faculty of Veterinary Medicine 
Universiti Putra Malaysia 
(Member) 
 
 
 
 
 
 
 
 
                                                                                          ____________________ 
                                                                                          AINI IDERIS, PhD 
                                                                                          Professor and Dean 
                                                                                          School of Graduate Studies 
      Universiti Putra Malaysia 
 
                                                                                          Date: 13 December 2007 
 
 
 x
DECLARATION 
 
I declare that the thesis is my original work except for quotations and citations which 
have been duly acknowledged. I also declare that it has not been previously, and is 
not concurrently, submitted for any other degree at Universiti Putra Malaysia or at 
any other institution. 
 
 
 
 
 
 
 
 
 
 
_______________________________ 
AHMAD FAIZAL ABDULL RAZIS 
 
Date: 6 November 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi
TABLE OF CONTENTS 
 
 Pag
e 
 
DEDICATION        
ABSTRACT          
ABSTRAK          
ACKNOWLEDGEMENTS        
APPROVAL           
DECLARATION          
LIST OF TABLES         
LIST OF FIGURES         
LIST OF ABBREVIATIONS      
  
 
ii 
iii 
v 
vii 
ix 
xi 
xv 
xvi 
xviii 
CHAPTER 
 
1  INTRODUCTION 
 
 
 
1 
 
2  LITERATURE REVIEW 
  2.1     Discovery and Characterization of Epidermal Growth      
                                  Factor 
  2.2     Biosynthesis and Tissue Distribution of EGF 
  2.3     Binding and metabolism of hEGF 
  2.4     Biological Effects of hEGF    
                        2.5     Genes and Structure of hEGF 
  2.6     Potential Clinical and Industrial Uses of hEGF 
  2.7     E. coli Expression System 
  2.8     Secretory production of recombinant proteins  
            using E. coli 
  2.9     Enhancement of secretion efficiency by manipulating      
    periplasmic chaperones 
  2.10   Expression of Recombinant hEGF in E. coli  
  2.11   Fusion proteins application  
  2.12   FLAG fusion proteins 
  2.13   Studies on the biological activities of hEGF 
 
4 
 
7 
8 
11 
13 
15 
17 
19 
 
24 
 
26 
28 
29 
31 
3  CLONING AND SEQUENCING OF hEGF GENE 
  3.1     Introduction  
                        3.2     Materials and Methods 
            3.2.1     Templates and Primers for Polymerase Chain    
                 Reaction (PCR) 
             3.2.2     Preparation of hEGF DNA Template  
                                  3.2.3     PCR Amplification of hEGF gene 
    3.2.4     Agarose Gel Electrophoresis 
    3.2.5     Purification of hEGF gene 
                                  3.2.6     Double Digestion of pFLAG-ATS and hEGF   
                                               gene                                  
    3.2.7     Cloning of hEGF gene into a pFLAG-ATS           
    3.2.8     Bacterial Cell Transformation 
 
33 
35 
35 
 
36 
36 
37 
37 
38 
 
38 
41 
 xii
                                  3.2.9     Identification and Verification of Positive    
                                               Clones 
    3.2.10   PCR Amplification of Positive Clones 
    3.2.11   Miniprep Plasmid Extraction 
    3.2.12   Restriction Enzyme Analysis 
    3.2.13   DNA sequencing of the hEGF Gene 
    3.2.14   Computer Analysis 
  3.3     Results 
    3.3.1     Amplification of hEGF Gene by the Polymerase   
                 Chain Reaction  
    3.3.2     Screening of Recombinant hEGF 
    3.3.3     The DNA Sequencing of the hEGF Gene 
  3.4     Discussion 
41 
 
42 
42 
43 
44 
44 
45 
45 
 
46 
47 
49 
4  EXPRESSION, ISOLATION AND PURIFICATION OF      
                  hEGF 
  4.1     Introduction 
  4.2     Materials and Methods 
    4.2.1     Expression of Recombinant hEGF  
    4.2.2     Optimization of Expression of Recombinant    
                 hEGF   
                                  4.2.3     Isolation of FLAG Fusion Proteins 
                                               4.2.3.1  Periplasmic Fraction by Osmotic Shock 
                                               4.2.3.2  Whole Cell Extract: Soluble and   
                                                            Insoluble Fractions 
                                  4.2.4     Immuno-Affinity Purification of FLAG Fusion   
                                               Proteins 
                 4.2.4.1   Purification of FLAG Fusion Proteins      
                               with the ANTI-FLAG M2 Affinity Gel 
                 4.2.4.2   Elution of the FLAG-fusion protein 
                                               4.2.4.3   Precipitation of FLAG-fusion protein 
                                               4.2.4.4   Removal of the FLAG peptide 
                                  4.2.5     SDS-PAGE analysis  
                                               4.2.5.1   Gel Preparation  
                 4.2.5.2   Sample Preparation  
                 4.2.5.3   Staining of SDS-PAGE                            
                                               4.2.5.4   Western Blotting analysis  
                                                             4.2.5.4.1   Preparation for Blotting of       
                                                                              SDS-PAGE 
                                                             4.2.5.4.2   Preparation of Trans-Blot  
                                                                              Transfer System 
                                                             4.2.5.4.3   Immunodetection of   
                                                                              Transferred Protein 
4.2.5.5  Dot-blot and Western blot analyses  of    
                                                             purified recombinant hEGF protein          
                                               4.2.5.6  Quantification of recombinant hEGF        
                                                             protein  
  4.3      Results 
             4.3.1    Expression of recombinant hEGF  
     4.3.2    Optimization of Expression of recombinant hEGF 
 
 
54 
55 
55 
56 
 
56 
56 
57 
 
57 
 
57 
 
58 
59 
59 
60 
60 
61 
61 
61 
61 
 
62 
 
62 
 
63 
 
63 
 
64 
64 
66 
 xiii
4.3.2.1 Periplasmic Fraction by Osmotic Shock 
Procedure 
4.3.2.2 Whole Cell Extract: Insoluble Fraction 
4.3.2.3 Effect of IPTG induction on the growth 
of recombinant hEGF and non-
recombinant hEGF  
4.3.2.4 Quantification of recombinant hEGF  
              protein by Sandwich ELISA  
                                   4.3.3   Immuno-Affinity Purification of FLAG Fusion      
               Protein 
  4.4     Discussion 
 
66 
 
68 
71 
 
 
73 
 
78 
 
81 
      5               GROWTH-STIMULATING ACTIVITY OF hEGF ON     
                       CULTURES OF HUMAN EPIDERMAL             
                       KERATINOCYTES AND HUMAN DERMAL   
                       FIBROBLASTS 
            5.1     Introduction 
            5.2     Materials and Methods 
                                 5.2.1    Cell Culture 
  5.2.1.1   Human Epidermal Keratinocytes 
  5.2.1.2   Human Dermal Fibroblasts 
                                 5.2.2    Cell Counting by Hemocytometer  
                                              5.2.2.1 Cells preparation 
                                              5.2.2.2   Slide Preparation 
                                              5.2.2.3   Analysis 
               5.2.3    Growth-stimulating activities of hEGF    
                                              5.2.3.1 BrdU Cell Proliferation Assay on HEK 
                                        5.2.3.2 MTT Cell Proliferation Assay on HDF 
                                 5.2.4     Percentage of growth-stimulating activity 
                                 5.2.5     Statistical Analysis 
            5.3    Results 
                                 5.3.1    BrdU Cell Proliferation Assay on HEK 
                                 5.3.2    MTT Cell Proliferation Assay on HDF 
            5.4    Discussion 
                                 5.4.1    BrdU Cell Proliferation Assay on HEK 
                                 5.4.2    MTT Cell Proliferation Assay on HDF 
 
 
 
 
 
94 
96 
96 
96 
96 
97 
97 
97 
98 
98 
98 
99 
100 
100 
101 
101 
107 
113 
113 
116 
6               SUMMARY, GENERAL CONCLUSION AND   
                 RECOMMENDATIONS FOR FUTURE RESEARCH 
 
REFERENCES 
APPENDICES 
BIODATA OF STUDENT 
LIST OF PUBLICATIONS 
120 
 
 
131 
144 
175 
176 
 
 
 
 
 
 
 xiv
 
LIST OF TABLES 
 
Table  
 
Page 
1 Amino acid sequence of Epidermal Growth Factor. 
 
5 
 
2 Signal sequences for the secretory production of recombinant 
proteins in Escherichia coli. 
 
20 
3 Quantification of recombinant hEGF protein as periplasmic 
fraction at different induction with 1.0 mM and 0.5 mM IPTG 
concentration. 
 
74 
4 Quantification of periplasmic fraction and whole cell insoluble 
fraction with induction of 1.0 mM IPTG. 
77 
5 Percentage of growth-stimulating activity of periplasmic hEGF 
on HEK after incubation at 24, 48 and 72 hours. 
 
102 
6 Percentage of growth-stimulating activity of periplasmic hEGF 
on HDF after incubation at 24, 48 and 72 hours. 
 
108 
7 Solutions for Preparing Resolving Gels for Tris-glycine SDS-
Polyacrylamide Gel Electrophoresis.  
146 
8 Solutions for Preparing 5% Stacking Gels for Tris-glycine 
SDS-   Polyacrylamide Gel Electrophoresis.  
146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xv
 
LIST OF FIGURES 
 
Figure  
 
Page 
1 Amino acid sequence of hEGF.
 
6 
2 Diagram of F-hEGF interaction with A-431 cells.  
 
11 
3 A-C Strategies for the secretory production of recombinant 
proteins in Escherichia coli.  
 
21 
4 Physical map of the pFLAG-ATS vector.  
 
40 
5 PCR amplification of hEGF gene.  
 
45 
6 PCR screening on the colonies of transformant.  
 
46 
7 Restriction enzyme (RE) analysis on recombinant hEGF.  
 
47 
8 The DNA sequence of the hEGF gene as compared to the 
established hEGF sequence (hEGF). 
 
48 
9 SDS-PAGE analysis of recombinant hEGF protein after 2 hours 
induction with 1.0 mM IPTG.  
 
65 
10 Western-blot analysis of recombinant hEGF protein after 2 hours 
induction with 1.0 mM IPTG using monoclonal anti-hEGF 
produced in mouse.  
 
65 
11 SDS-PAGE analysis for periplasmic fraction of recombinant 
hEGF protein at 0, 2, 4 and 6 hours post-induction.  
 
67 
12 Western-blot analysis for periplasmic fraction of recombinant 
hEGF protein at 0, 2, 4 and 6 hours post-induction using 
monoclonal anti-hEGF produced in mouse (Sigma Aldrich, 
U.S.A.).  
 
67 
13 Western-blot analysis for periplasmic fraction of recombinant 
hEGF protein at 0, 2, 4 and 6 hours post-induction using ANTI-
FLAG® mouse monoclonal antibodies M1 (IgG2b) (Sigma 
Aldrich, U.S.A.). 
 
68 
14 SDS-PAGE analysis for whole cell insoluble fraction of 
recombinant hEGF protein at 0, 2, 4 and 6 hours post-induction.  
 
70 
15 Western-blot analysis for whole cell insoluble fraction of 
recombinant hEGF protein at 0, 2, 4 and 6 hours pos-induction 
using monoclonal anti-hEGF produced in mouse (Abcam, 
U.S.A.). 
70 
 xvi
 
16 Effect of IPTG induction on the growth of recombinant hEGF 
(pFLAG-EGF) and non-recombinant hEGF (pFLAG-ATS). 
 
72 
17 Effect of IPTG induction at different concentration on the growth 
of recombinant hEGF.  
 
72 
18 Interaction analysis between time of post-induction and different 
IPTG concentration used in the production of recombinant hEGF 
protein.  
 
75 
19 Comparison of periplasmic fraction with induction of 0.5 mM and 
1.0 mM IPTG concentration.  
 
76 
20 The comparison between whole cell insoluble fraction and 
periplasmic fraction with induction of 1.0 mM IPTG 
concentration.  
 
79 
21 Dot-blot assay by chemiluminescent detection kit of purified 
recombinant hEGF protein for periplasmic fraction and whole cell 
insoluble fraction using monoclonal anti-hEGF produced in 
mouse (Abcam, U.S.A.).  
 
79 
22 SDS-PAGE analysis of purified recombinant hEGF protein for 
periplasmic fraction and whole cell insoluble fraction.  
 
80 
23 Western-blot analysis of purified recombinant hEGF protein for 
periplasmic fraction and whole cell insoluble fraction using 
monoclonal anti-hEGF produced in mouse (Abcam, U.S.A.).  
 
80 
24 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HEK at 24 hour incubation. 
 
104 
25 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HEK at 48 hour incubation. 
 
105 
26 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HEK at 72 hour incubation. 
 
106 
27 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HDF at 24 hour incubation.  
 
110 
28 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HDF at 48 hour incubation. 
 
111 
29 Comparison of growth-stimulating activity between standard 
hEGF and periplasmic hEGF on HDF at 72 hour incubation. 
 
112 
 
 
 xvii
 
LIST OF ABBREVIATIONS 
 
51Cr-labeled 51Chromium-labeled 
Amp  Ampicillin 
ARF  Acute Renal Failure 
ATCC  American Type Culture Collection 
  
BrdU  Bromodeoxyuridine 
 
BSA  Bovine Serum Albumin 
BUN  Blood Urea Nitrogen 
C-terminal Carboxyl-terminal 
DAB  3, 3’-diaminobenzidine 
E. coli Escherichia coli 
EBA   Expanded Bed Adsorption  
EGF  Epidermal Growth Factor 
EGF-R  Epidermal Growth Factor Receptor 
fMet   N-formyl methionine   
FTNF  Feline Tumor Necrosis Factor 
HB-EGF Heparin binding EGF-like growth factor 
HDF  Human Dermal Fibroblasts 
hEGF  Human Epidermal Growth Factor 
HEK  Human Epidermal Keratinocytes 
hOB  Human obese 
K1 (SK) Kringle 1 (Streptokinase) 
MCS  Multiple cloning site 
mEGF  Mouse Epidermal Growth Factor 
MRC-5 Normal Human Fetal Lung Fibroblast 
 xviii
 xix
NHEK  Normal Human Epidermal Keratinocytes 
NMWL Nominal Molecular Weight Limit 
N-terminal  Amino-terminal 
OmpA  Outer membrane protein A 
ORF  Open Reading Frame 
Prepro Protein precursor 
 
rEGF  Rat Epidermal Growth Factor 
 
T3 Triiodothyronine 
TGFα  Transforming Growth Factor alpha 
TNF  Tumor Necrosis Factor 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
Human epidermal growth factor (hEGF), consisting of 53 amino acid residues, is a 
single chain polypeptide with a molecular weight of about 6,200 Da. hEGF is 
considered to be identical with human urogastrone (Gregory, 1975), which is 
produced by the human duodenum and salivary glands (Cohen and Carpenter, 1975). 
hEGF is widely used in clinical and cosmetic fields because it stimulates the growth 
of a variety of cell types in cultures as well as the growth and differentiation of 
certain tissues in vivo (Carpenter and Cohen, 1979). It also promotes protein 
synthesis, RNA synthesis and metabolic uptake in epidermal cells (Kim and Muller, 
1999), repairs corneal wounds and gastric ulcers and inhibits the proliferation of 
human gastric cancer cells (Jiang et al., 1999; Reim et al., 1988).  Besides, hEGF has 
been observed to have many biological actions both in vitro and in vivo including 
proliferative effects on fibroblasts, keratinocytes and epithelial cells. 
 
Since the finding of hEGF properties as strong anti-ulcer (Gregory, 1975) and 
growth-stimulating factors (Hashimoto et al., 1994), the sufficient production for 
medical application has been in great demand. Conventional method such as 
recovery of hEGF from human urine via complicated steps is established (Starkey et 
al., 1975). However, it failed to provide sufficient amount of homogenous hEGF 
with well-defined quality for clinical application and inappropriate for human 
consumption.  
 
Many studies have reported using recombinant DNA technique to produce high 
hEGF productivity. However, the cytoplasmic expression of heterologous protein in 
E. coli, particularly small peptides, has encountered many obstacles. It is commonly 
found that proteins expressed in this form are rapidly degraded by proteases within 
the cell (Skipper et al., 1985). It was reported that the hEGF expressed in high 
density precipitated intracellularly form aggregates called inclusion bodies (Shimizu 
et al., 1991). This causes the expressed proteins to be severely misfolded. Although 
there are many protocols available for refolding this protein, the production is 
inefficient and the procedure is costly.  
 
Thus, to obtain hEGF in sufficient quantities for this study, the recombinant hEGF is 
developed. It is desirable that recombinant hEGF be secreted into the cell growth 
medium. Purification of this protein would then be simpler for an intracellular 
protein as the product would not be contaminated with cytoplasmic components. In 
addition, the formation of inclusion bodies would be avoided and possible toxic 
effects of the hEGF polypeptide product on the host cell would be reduced.  
 
In this study, a secretory plasmid is used, which contains strong regulatory elements 
such as tac promoter, the consensus ribosome-binding site, and the ompA leader 
sequence for efficient expression and secretion of hEGF in E. coli. This plasmid also 
encodes a lac repressor and an ampicillin (Amp) resistance gene. It was shown that 
secretory recombinant E. coli system was able to express and accumulate authentic 
hEGF in the culture medium (Wong and Sutherland, 1993). Normally, the secretion 
of high-level expressed protein in E. coli will eventually elicit a stress response in the 
host such as energy drain, membrane perturbation and lethal effect which leads to the 
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phenomenon known as “overproduction lethality”. Andersson et al. (1996) suggested 
that overexpression of foreign protein was due to the appearance of non-culturable 
cells which do not lose all metabolic activities and even continued to maintain 
glucose uptake and respiratory ability. However, only few studies reported the 
optimization of conditions for the process control in the expression and secretion of 
hEGF in E. coli.   
 
In the present study, recombinant hEGF is expressed as a fusion protein using 
pFLAG expression system (Sigma, U.S.A.). This system allows recombinant protein 
to be expressed as a fusion protein containing the FLAG peptide sequence. 
Monoclonal antibodies recognizing the FLAG peptide can then be used to purify the 
fusion protein using affinity chromatography. The purification of hEGF protein has 
been made more convenient and efficient by using this system.    
                                                                                                                                                    
The aim of this study is to express the recombinant hEGF in E. coli and study the 
growth-stimulating activity of hEGF on human epidermal keratinocytes and human 
dermal fibroblasts cultures. The objectives involved in this study were:- 
1. cloning and sequencing of hEGF gene. 
2. expression, isolation and purification of hEGF. 
3. determination of the growth-stimulating activity of hEGF on human 
epidermal keratinocytes and human dermal fibroblasts cultures.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Discovery and Characterization of Epidermal Growth Factor 
Epidermal growth factor (EGF) was discovered as a contaminant of nerve growth 
factor in 1960 by Stanley Cohen (Cohen, 1962). EGF was recognized by its ability to 
accelerate the eruption of mouse teeth and the opening of eyelids of newborn mice. 
The abundance of EGF in mouse salivary glands facilitated its purification and in 
1972 the full amino acid sequence of mouse EGF was determined (Savage et al., 
1972). Although no human equivalent of EGF had been purified during that time, it 
was known that a similar protein was present in concentrates of human urine 
(Starkey et al., 1975). The human urinary protein responsible for the inhibition of 
gastric acid secretion (β-urogastrone) was finally purified and analyzed. Harry 
Gregory (1975) recognized that the amino acid composition of murine EGF, human 
urinary EGF and β-urogastrone were closely related. The biology of urogastrone 
indicated that it might also promote the proliferation and epithelialization of gastric 
mucosa, so he concluded that urogastrone and human epidermal growth factor are 
one and the same (Gregory, 1975). The amino acid sequence of EGF is as displayed 
in Table 1. 
 
 
 
Table 1. Amino acid sequence of Epidermal Growth Factor 
 
 
EGF                               AMINO ACID SEQUENCE 
 
rat EGF N S N T G C P P S Y D G Y C L N G G V C M YV E S V D RY V C N C V I G Y I  G E R C Q H R D L R  
mouse EGF N S Y P G C P S S Y D G Y C L N G G V C M H I  E S L D S Y T C N C V I G Y S G D R C Q T R D L R W W E L R 
guinea pig EGF Q D A P G C P P S H D G Y C L H G G V C M H I E S L N T Y A C N C V I G Y VG E R C E H Q D L D D W  E 
human EGF N S D S  E C P L S H D G Y C L H D G V C M Y I E AL D K Y A C N C V VGY  I G E R C Q Y R D L K W W E L R 
 
 
(Source: Burgess, 1989) 
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